BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

775 related articles for article (PubMed ID: 33716056)

  • 21. Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.
    Feld J; Tremblay D; Navada SC; Silverman LR
    Leuk Lymphoma; 2023 Mar; 64(3):525-539. PubMed ID: 36370098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
    Voso MT; Leone G; Piciocchi A; Fianchi L; Santarone S; Candoni A; Criscuolo M; Masciulli A; Cerqui E; Molteni A; Finelli C; Parma M; Poloni A; Carella AM; Spina F; Cortelezzi A; Salvi F; Alessandrino EP; Rambaldi A; Sica S
    Ann Oncol; 2017 Jul; 28(7):1547-1553. PubMed ID: 28368509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review.
    Haumschild R; Kennerly-Shah J; Barbarotta L; Zeidan AM
    J Oncol Pharm Pract; 2024 Jun; 30(4):721-736. PubMed ID: 38509812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studies.
    Pan T; Qi J; You T; Yang L; Wu D; Han Y; Zhu L
    Leuk Res; 2018 Aug; 71():13-24. PubMed ID: 29936305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efficacy and safety of venetoclax combined with azacitidine versus CAG regimen combined with decitabine in elderly patients with relapsed acute myeloid leukemia].
    Wang P; Zhang LW; Lu CQ; Wang TZ; Shan M; Xiao JY; Tian H; Ma X; Xu Y; Wu DP
    Zhonghua Nei Ke Za Zhi; 2022 Feb; 61(2):157-163. PubMed ID: 35090250
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy of epigenetic agents for older patients with acute myeloid leukemia and myelodysplastic syndrome in randomized controlled trials: a systematic review and network meta-analysis.
    Oh S; Kim E
    Clin Exp Med; 2023 Oct; 23(6):2705-2714. PubMed ID: 36964818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
    Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E
    Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The clinical safety and efficacy of low dose subcutaneous decitabine in treating acute myeloid leukemia and intermediate- or higer-risk myelodysplastic syndromes in the elderly patients].
    Ai H; Wei XD; Yin QS; Wang P; Mi RH; Yuan FF; Chen L; Song YP
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):606-609. PubMed ID: 28789495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the 'real life' setting: A single center observational study.
    Papageorgiou SG; Vasilatou D; Kontos CK; Foukas P; Kefala M; Ioannidou ED; Bouchla A; Bazani E; Dimitriadis G; Pappa V
    Hematology; 2016 Jan; 21(1):34-41. PubMed ID: 26218077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing DNA hypomethylating therapy in acute myeloid leukemia and myelodysplastic syndromes.
    Straube J; Lane SW; Vu T
    Bioessays; 2021 Oct; 43(10):e2100125. PubMed ID: 34463368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L; Greil R
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.
    Pepe S; Scalzulli E; Colafigli G; Di Prima A; Diverio D; Mancini M; Latagliata R; Martelli M; Foà R; Breccia M
    Ann Hematol; 2020 Oct; 99(10):2405-2416. PubMed ID: 32813071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes.
    Finelli C; Follo MY; Stanzani M; Parisi S; Clissa C; Mongiorgi S; Barraco M; Cocco L
    Curr Pharm Des; 2016; 22(16):2349-57. PubMed ID: 26960675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC).
    DeZern AE; Zeidan AM; Barnard J; Hand W; Al Ali N; Brown F; Zimmerman C; Roboz GJ; Garcia-Manero G; Steensma DP; Komrokji RS; Sekeres MA;
    Leuk Lymphoma; 2017 Jun; 58(6):1325-1331. PubMed ID: 27774847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
    Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
    Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
    Ye XN; Zhou XP; Wei JY; Xu GX; Li Y; Mao LP; Huang J; Ren YL; Mei C; Wang JH; Lou YJ; Ma LY; Yu WJ; Ye L; Xie LL; Luo YW; Hu C; Niu LM; Dou MH; Jin J; Tong HY
    Leuk Lymphoma; 2016; 57(6):1311-8. PubMed ID: 26372888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group.
    Lübbert M; Suciu S; Hagemeijer A; Rüter B; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Muus P; Pflüger KH; Schaefer HE; Bogatyreva L; Aul C; de Witte T; Ganser A; Becker H; Huls G; van der Helm L; Vellenga E; Baron F; Marie JP; Wijermans PW;
    Ann Hematol; 2016 Jan; 95(2):191-9. PubMed ID: 26596971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decitabine plus thalidomide yields more sustained survival rates than decitabine monotherapy for risk-tailored elderly patients with myelodysplastic syndrome.
    Zhao WH; Zeng QC; Huang BT; Li BS; Chen RL
    Leuk Res; 2015 Apr; 39(4):424-8. PubMed ID: 25721158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.
    Cabrero M; Jabbour E; Ravandi F; Bohannan Z; Pierce S; Kantarjian HM; Garcia-Manero G
    Leuk Res; 2015 May; 39(5):520-4. PubMed ID: 25828745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.